Investor's Business Daily on MSN
Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot
Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved ...
Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, ...
Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...
Wall Street expected sales of Yeztugo, which has an annual U.S. list price of about $28,000, at $37.5 million, according to ...
Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil ...
In the ongoing fight against viruses, a new scientific approach could bring sweeping change. Instead of targeting the virus ...
Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...
Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...
Low CD4+ cell count, STI coinfection, new ART initiation, and patient race predicted mpox-related hospitalization among patients with HIV coinfection.
Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...
Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback